KR101180174B1 - 신규한 벤즈아미드 유도체 - Google Patents

신규한 벤즈아미드 유도체 Download PDF

Info

Publication number
KR101180174B1
KR101180174B1 KR1020100038039A KR20100038039A KR101180174B1 KR 101180174 B1 KR101180174 B1 KR 101180174B1 KR 1020100038039 A KR1020100038039 A KR 1020100038039A KR 20100038039 A KR20100038039 A KR 20100038039A KR 101180174 B1 KR101180174 B1 KR 101180174B1
Authority
KR
South Korea
Prior art keywords
methyl
formula
amino
chloro
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020100038039A
Other languages
English (en)
Korean (ko)
Other versions
KR20110118446A (ko
Inventor
김순회
임원빈
최성학
최선호
손주희
성현정
김미연
조강훈
손태경
Original Assignee
동아제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020100038039A priority Critical patent/KR101180174B1/ko
Application filed by 동아제약주식회사 filed Critical 동아제약주식회사
Priority to PCT/KR2011/002759 priority patent/WO2011132901A2/en
Priority to RU2012150037/04A priority patent/RU2536688C2/ru
Priority to AU2011243393A priority patent/AU2011243393B2/en
Priority to ES11772189.4T priority patent/ES2594708T3/es
Priority to PH1/2012/501843A priority patent/PH12012501843A1/en
Priority to CA2794176A priority patent/CA2794176C/en
Priority to SG2012072450A priority patent/SG184350A1/en
Priority to MX2012011721A priority patent/MX2012011721A/es
Priority to JP2013506071A priority patent/JP5564147B2/ja
Priority to NZ602612A priority patent/NZ602612A/en
Priority to US13/641,867 priority patent/US9221790B2/en
Priority to HK13103256.8A priority patent/HK1176061B/xx
Priority to CN201180020476.6A priority patent/CN102844301B/zh
Priority to BR112012026509-1A priority patent/BR112012026509B1/pt
Priority to MYPI2012004698A priority patent/MY162554A/en
Priority to EP11772189.4A priority patent/EP2560955B1/en
Priority to UAA201213255A priority patent/UA107702C2/ru
Publication of KR20110118446A publication Critical patent/KR20110118446A/ko
Publication of KR101180174B1 publication Critical patent/KR101180174B1/ko
Application granted granted Critical
Priority to IL222491A priority patent/IL222491A/en
Priority to ZA2012/07903A priority patent/ZA201207903B/en
Assigned to 동아에스티 주식회사 reassignment 동아에스티 주식회사 권리의 전부이전등록 Assignors: 동아쏘시오홀딩스 주식회사
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
KR1020100038039A 2010-04-23 2010-04-23 신규한 벤즈아미드 유도체 Active KR101180174B1 (ko)

Priority Applications (20)

Application Number Priority Date Filing Date Title
KR1020100038039A KR101180174B1 (ko) 2010-04-23 2010-04-23 신규한 벤즈아미드 유도체
CN201180020476.6A CN102844301B (zh) 2010-04-23 2011-04-18 新苯甲酰胺衍生物
AU2011243393A AU2011243393B2 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives
ES11772189.4T ES2594708T3 (es) 2010-04-23 2011-04-18 Derivados novedosos de benzamida
PH1/2012/501843A PH12012501843A1 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives
CA2794176A CA2794176C (en) 2010-04-23 2011-04-18 Novel benzamide derivatives
SG2012072450A SG184350A1 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives
MX2012011721A MX2012011721A (es) 2010-04-23 2011-04-18 Derivados benzamida novedosos.
JP2013506071A JP5564147B2 (ja) 2010-04-23 2011-04-18 新規なベンズアミド誘導体
RU2012150037/04A RU2536688C2 (ru) 2010-04-23 2011-04-18 Новые бензамидные производные
PCT/KR2011/002759 WO2011132901A2 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives
HK13103256.8A HK1176061B (zh) 2010-04-23 2011-04-18 新苯甲酰胺衍生物
MYPI2012004698A MY162554A (en) 2010-04-23 2011-04-18 Novel benzamide derivatives
US13/641,867 US9221790B2 (en) 2010-04-23 2011-04-18 Benzamide derivatives
BR112012026509-1A BR112012026509B1 (pt) 2010-04-23 2011-04-18 composto derivado de benzamida, métodos para preparar o dito composto ou um sal farmaceuticamente aceitável deste e uso do mesmo para prevenção, tratamento ou alívio de uma doença devida à eficácia atenuada de um receptor 5-ht4 em um mamífero
EP11772189.4A EP2560955B1 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives
UAA201213255A UA107702C2 (xx) 2010-04-23 2011-04-18 Похідні бензаміду
NZ602612A NZ602612A (en) 2010-04-23 2011-04-18 Novel benzamide derivatives
IL222491A IL222491A (en) 2010-04-23 2012-10-16 Compounds of benzamide for the treatment of 5-ht4 receptor-related disorders, pharmaceuticals containing them and a method for preparing these compounds
ZA2012/07903A ZA201207903B (en) 2010-04-23 2012-10-19 Novel benzamide derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100038039A KR101180174B1 (ko) 2010-04-23 2010-04-23 신규한 벤즈아미드 유도체

Publications (2)

Publication Number Publication Date
KR20110118446A KR20110118446A (ko) 2011-10-31
KR101180174B1 true KR101180174B1 (ko) 2012-09-05

Family

ID=44834616

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100038039A Active KR101180174B1 (ko) 2010-04-23 2010-04-23 신규한 벤즈아미드 유도체

Country Status (19)

Country Link
US (1) US9221790B2 (enExample)
EP (1) EP2560955B1 (enExample)
JP (1) JP5564147B2 (enExample)
KR (1) KR101180174B1 (enExample)
CN (1) CN102844301B (enExample)
AU (1) AU2011243393B2 (enExample)
BR (1) BR112012026509B1 (enExample)
CA (1) CA2794176C (enExample)
ES (1) ES2594708T3 (enExample)
IL (1) IL222491A (enExample)
MX (1) MX2012011721A (enExample)
MY (1) MY162554A (enExample)
NZ (1) NZ602612A (enExample)
PH (1) PH12012501843A1 (enExample)
RU (1) RU2536688C2 (enExample)
SG (1) SG184350A1 (enExample)
UA (1) UA107702C2 (enExample)
WO (1) WO2011132901A2 (enExample)
ZA (1) ZA201207903B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015012515A1 (ko) 2013-07-25 2015-01-29 동아에스티 주식회사 벤즈아미드 유도체의 제조방법, 그의 제조에 사용되는 새로운 중간체 및 상기 중간체의 제조방법

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물
KR101457789B1 (ko) 2013-02-13 2014-11-03 동아제약 주식회사 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법
CN104230889A (zh) * 2014-08-29 2014-12-24 南京大学 环丙沙星衍生物及其制备方法与用途
KR102394635B1 (ko) * 2015-03-31 2022-05-09 (주)아모레퍼시픽 5-아다만탄-1-일-n-(2,4-다이하이드록시벤질)-2,4-다이메톡시벤즈아마이드를 함유하는 항산화 또는 항노화 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100500372B1 (ko) 1997-07-11 2005-07-11 얀센 파마슈티카 엔.브이. 위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 비사이클릭 벤즈아미드
US20100093801A1 (en) 2008-10-14 2010-04-15 Sk Holdings Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507462A (en) 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
EP0774460A1 (en) 1994-03-30 1997-05-21 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compound and use thereof as medicine
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
KR20010081034A (ko) * 1998-11-20 2001-08-25 프리돌린 클라우스너, 롤란드 비. 보레르 피페리딘 씨씨알-3 수용체 길항제
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
ES2526338T3 (es) 2007-04-19 2015-01-09 Dong-A Pharm.Co., Ltd. Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad
WO2010062959A1 (en) 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
BR112012023139A2 (pt) 2010-03-24 2018-06-26 Dong A Pharm Co Ltd composição farmacêutica para a prevenção ou o tratamento de doença do fígado gordo não alcóolico e o método para a prevenção ou tratamento de doença do fígado gordo não alcóolico usando a mesma.
SG190415A1 (en) 2010-11-24 2013-06-28 Dong A St Co Ltd Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
JP5599519B2 (ja) 2010-11-24 2014-10-01 ドン−ア エスティ カンパニー リミテッド キノリン誘導体化合物、その製造方法およびそれを含む薬学組成物
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100500372B1 (ko) 1997-07-11 2005-07-11 얀센 파마슈티카 엔.브이. 위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 비사이클릭 벤즈아미드
KR100885658B1 (ko) 1997-07-11 2009-02-25 얀센 파마슈티카 엔.브이. 위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 모노사이클릭 벤즈아미드
US20100093801A1 (en) 2008-10-14 2010-04-15 Sk Holdings Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015012515A1 (ko) 2013-07-25 2015-01-29 동아에스티 주식회사 벤즈아미드 유도체의 제조방법, 그의 제조에 사용되는 새로운 중간체 및 상기 중간체의 제조방법
KR20150013018A (ko) 2013-07-25 2015-02-04 동아에스티 주식회사 벤즈아미드 유도체의 제조방법, 그의 제조에 사용되는 새로운 중간체 및 상기 중간체의 제조방법

Also Published As

Publication number Publication date
MX2012011721A (es) 2012-12-17
CA2794176C (en) 2015-12-15
RU2536688C2 (ru) 2014-12-27
BR112012026509B1 (pt) 2021-01-19
CN102844301B (zh) 2015-04-22
RU2012150037A (ru) 2014-05-27
EP2560955A4 (en) 2013-09-11
US20130085160A1 (en) 2013-04-04
MY162554A (en) 2017-06-15
AU2011243393A1 (en) 2012-10-18
WO2011132901A2 (en) 2011-10-27
AU2011243393B2 (en) 2014-07-17
ZA201207903B (en) 2013-06-26
BR112012026509A2 (pt) 2017-10-31
IL222491A0 (en) 2012-12-31
JP5564147B2 (ja) 2014-07-30
NZ602612A (en) 2014-11-28
SG184350A1 (en) 2012-11-29
CA2794176A1 (en) 2011-10-27
WO2011132901A3 (en) 2012-01-26
PH12012501843A1 (en) 2013-01-07
IL222491A (en) 2016-07-31
EP2560955B1 (en) 2016-06-29
UA107702C2 (xx) 2015-02-10
CN102844301A (zh) 2012-12-26
KR20110118446A (ko) 2011-10-31
JP2013525344A (ja) 2013-06-20
US9221790B2 (en) 2015-12-29
EP2560955A2 (en) 2013-02-27
ES2594708T3 (es) 2016-12-22
HK1176061A1 (en) 2013-07-19

Similar Documents

Publication Publication Date Title
DE60112791T2 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
DE69719191T2 (de) Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
US8293917B2 (en) Pyrazole compounds as CCR1 antagonists
US20080108660A1 (en) Benzimidazolone Carboxylic Acid Derivatives
AU2012358359A1 (en) Non-systemic TGR5 agonists
JP5587246B2 (ja) レニン阻害剤としての３，４−置換ピペリジン誘導体
DE69704060T2 (de) Tetrahydroisochinolinderivate und ihre pharmazeutische anwendung
JP5564147B2 (ja) 新規なベンズアミド誘導体
JPWO2010107115A1 (ja) グリシントランスポーター阻害物質
JP2023553291A (ja) Ｔｒｐｍ３媒介性障害を治療するためのアリール誘導体
AU781837B2 (en) 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
JP6498672B2 (ja) 疼痛に対して多重モードの活性を有するピペリジン化合物
CN101522197B (zh) 尾加压素ⅱ受体拮抗剂
TW200924774A (en) Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5
JP2008501732A (ja) Ｃｃｒ５拮抗剤としての化合物
US7737163B2 (en) Benzimidazolone carboxylic acid derivatives
TW382016B (en) 4-[(thien-2yl)methyl]-imidazole analgesics
KR20010031839A (ko) 한 개의 질소원자를 함유하는 5, 6 또는 7원헤테로사이클릭 환으로 치환된 이미다조일알킬
JP6772251B2 (ja) オレキシン受容体拮抗薬の化合物の結晶形およびその製造方法と使用
JP4943826B2 (ja) 医薬組成物
WO2002006272A1 (fr) Derives de polyfluoroalkyltriazole, leur preparation et leur utilisation en therapeutique
TWI917479B (zh) 用於治療ｔｒｐｍ３介導病症之芳基衍生物
HK1176061B (zh) 新苯甲酰胺衍生物
JP2008542379A (ja) ブラジキニンアンタゴニストとしての１−ヒドロキシシクロアルカンカルボキサミド誘導体
JPWO1996038420A1 (ja) 単環系アミンを有するインダゾール誘導体

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20100423

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20111227

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120829

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120830

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120830

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20141211

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20141211

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20151230

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20161222

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20161222

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20171219

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20171219

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20181217

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20181217

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20191126

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20191126

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20201123

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20201123

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20211123

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20211123

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20221117

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20221117

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20231128

Start annual number: 13

End annual number: 13